Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Cellular Oncology (Dordrecht, Netherlands)|August 29, 2020
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemiaJorge Antonio Elias Godoy Carlos, Keli Lima, Juan Luiz Coelho-Silva, et al.
Cell Death Discovery|March 25, 2026
Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemiaManuela Albuquerque de Melo, Brunno Gilberto Santos de Macedo, Diego A Pereira-Martins, et al.
Stem Cells and Development|January 14, 2014
Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesionFernanda Marconi Roversi, Matheus Rodrigues Lopes, João Agostinho Machado-Neto, et al.
Haematologica|July 10, 2012
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaSarah Abu Kar, Anna Jankowska, Hideki Makishima, et al.
Investigational New Drugs|January 11, 2022
Phenformin increases early hematopoietic progenitors in the Jak2<sup>V617F</sup> murine modelAntônio Bruno Alves-Silva, Bruna Alves Fenerich, Natasha Peixoto Fonseca, et al.
Oncotarget|January 13, 2016
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasmsPaula de Melo Campos, João A Machado-Neto, Christopher A Eide, et al.
Leukemia Research|August 21, 2014
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412Paula de Melo Campos, João A Machado-Neto, Renata Scopim-Ribeiro, et al.
Hematological Oncology|December 28, 2025
Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET TrialPaula de Melo Campos, Kátia Borgia Barbosa Pagnano, Fernanda Soares Niemann, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|November 15, 2016
Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathwayFernanda Marconi Roversi, Fernando Vieira Pericole, João Agostinho Machado-Neto, et al.
European Journal of Pharmacology|April 17, 2026
Quizartinib-induced resistance drives clonal emergence of MV4-11 cells with molecular alterations enabling multidrug antileukemic escapeLivia Bassani Lins de Miranda, Keli Lima, Diego A Pereira-Martins, et al.
Pageof 11